Cibus partners with AgVayā to introduce gene-editing technologies for India's rice industry, enhancing productivity and sustainability.
Quiver AI Summary
Cibus, Inc. has entered into a strategic partnership with AgVayā to enhance its presence in the Indian agriculture sector, specifically focusing on the rice seed industry. The collaboration aims to develop market strategies and foster partnerships that will help introduce Cibus' gene-editing technologies to improve rice varieties, making them more resilient and productive. This initiative is crucial for India's agricultural economy, as the country is the second-largest rice producer globally. Cibus plans to work with various stakeholders, including industry players and government entities, to tackle significant agricultural challenges and accelerate the commercialization of advanced seed technologies. The partnership highlights Cibus' commitment to innovation in rice production and supporting global food security.
Potential Positives
- This collaboration with AgVayā positions Cibus to effectively enter and influence the Indian agriculture market, particularly in the vital rice industry.
- The partnership aims to develop new gene-edited rice varieties that enhance resilience and productivity, addressing significant agricultural challenges in India.
- Cibus seeks to accelerate the breeding process for rice in India by over a decade, which could significantly benefit local agriculture and food security.
- This agreement signifies Cibus' commitment to global agricultural innovation and expanding its technological applications, highlighting its role in supporting sustainability and productivity in major food crops.
Potential Negatives
- Significant reliance on a strategic partner, AgVayā, may expose Cibus to risks if the partnership does not yield anticipated results or if AgVayā fails to deliver on its commitments.
- The press release includes multiple forward-looking statements that highlight financial uncertainties and dependencies, such as the need for additional funding, which may raise concerns among investors about the company's financial stability.
- Potential regulatory challenges associated with gene-editing processes could impact Cibus's ability to successfully introduce its technologies in India and elsewhere, posing long-term risks to its business model.
FAQ
What is the partnership between Cibus and AgVayā focused on?
The partnership aims to develop strategies and solutions for India’s rice seed industry using gene editing technologies.
Why is the Indian rice industry important?
India is the world's second-largest producer of rice, crucial for its agricultural economy and global food security.
How will Cibus' technologies benefit Indian farmers?
Cibus' gene editing technologies will help create resilient rice varieties, lower costs, and reduce pesticide dependence.
What specific challenges are Cibus and AgVayā addressing?
They will tackle major agricultural challenges in rice, including sustainability, productivity, and market access for farmers.
How does this collaboration fit into Cibus’ global strategy?
This agreement is part of Cibus’ broader strategy to expand its gene-editing technology into key agricultural markets worldwide.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CBUS Hedge Fund Activity
We have seen 27 institutional investors add shares of $CBUS stock to their portfolio, and 44 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 2,572,561 shares (+55.7%) to their portfolio in Q2 2025, for an estimated $3,550,134
- ARMISTICE CAPITAL, LLC removed 1,948,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $2,688,240
- GRATIA CAPITAL, LLC added 857,000 shares (+inf%) to their portfolio in Q2 2025, for an estimated $1,182,660
- BLACKROCK, INC. removed 642,919 shares (-57.2%) from their portfolio in Q2 2025, for an estimated $887,228
- STATE STREET CORP removed 241,169 shares (-76.1%) from their portfolio in Q2 2025, for an estimated $332,813
- GEODE CAPITAL MANAGEMENT, LLC removed 215,871 shares (-45.6%) from their portfolio in Q2 2025, for an estimated $297,901
- MILLENNIUM MANAGEMENT LLC added 183,524 shares (+inf%) to their portfolio in Q2 2025, for an estimated $253,263
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CBUS Analyst Ratings
Wall Street analysts have issued reports on $CBUS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 05/12/2025
To track analyst ratings and price targets for $CBUS, check out Quiver Quantitative's $CBUS forecast page.
Full Release
SAN DIEGO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company specializing in the development and licensing of gene-edited plant traits, today announced its agreement with AgVayā, a strategic growth advisory firm that partners with leading innovators, to develop strategies and solutions for the Indian agriculture market. Together, the companies will define market strategies, build partnerships, and accelerate the introduction of Cibus’ gene editing technologies into India’s rice seed industry, supporting the development of more resilient and productive rice varieties that are critical to both India’s agricultural economy and the global rice supply. Working through AgVayā, Cibus will actively partner with industry and government stakeholders across India to address some of the country’s biggest agricultural challenges in rice, while inviting R&D and commercial collaborations to accelerate impact.
India is the world’s second-largest producer and the largest exporter of rice, with approximately 50 million hectares (125 million acres) under cultivation. As a cornerstone of Indian agriculture and a critical contributor to the national economy and food security across Asia, rice presents both enormous opportunities and pressing challenges. Modern gene editing technologies create solutions to drive affordable costs, accelerate the breeding cycle, and lower dependence on pesticides.
“This partnership represents a significant milestone for Cibus as we work to extend our innovative gene editing technologies to support one of the world’s most important rice-producing regions,” said Peter Beetham, Ph.D., co-founder and Interim CEO of Cibus. “With more than 25 years of technical expertise and exciting ongoing trait development in rice, we are excited to work alongside AgVayā’s experienced team to introduce high-performance seed solutions to Indian farmers. Our goal is to foster meaningful collaborations across India’s decentralized agricultural ecosystem to address critical challenges through cutting-edge innovation.”
Through this agreement, Cibus and AgVayā will work together to develop a comprehensive strategy to expand Cibus’ presence in India, partnering with companies, institutions, and government stakeholders to tackle key challenges in the rice industry. The collaboration will focus on enabling joint development and commercialization of advanced herbicide and sustainability traits, creating opportunities for Indian rice seed companies and public agencies to integrate cutting-edge gene editing solutions. By leveraging Cibus’ gene-editing technologies, Cibus aims to accelerate breeding timelines in India by more than a decade, make modern seed technologies more accessible, and reduce dependence on pesticides, all in support of developing climate-resilient, high-yielding rice seed varieties adapted to evolving agronomic and environmental conditions worldwide.
“We are proud to help bring Cibus’ world-class gene editing technologies to strategic crops of interest to India,” said Sekhar Natarajan, Partner of AgVayā. “Rice is central to India’s agricultural economy, and the integration of advanced seed technologies has the potential to transform productivity, sustainability, and farmer prosperity. By combining Cibus’ innovations with AgVayā’s strategic relationships and market expertise, we aim to accelerate the adoption of these technologies, driving scalable, long-term improvements that strengthen India’s rice industry and support global food security.”
This agreement follows Cibus’ recent announcement of a material transfer agreement with Centro Internacional de Agricultura Tropical (CIAT), in collaboration with the Latin American Fund for Irrigated Rice (FLAR), to introduce Cibus’ HT3 clethodim herbicide tolerance trait into elite rice germplasm for Latin America, underscoring Cibus’ commitment to advancing rice innovation globally.
About Cibus
Cibus is leading a new era in agriculture. The company is a technology leader developing and licensing advanced plant traits that enable higher yields, lower input costs, and more sustainable farming. Using proprietary precision gene editing and breeding systems, Cibus can develop traits with remarkable speed and accuracy, at a fraction of the time and cost of conventional breeding or GMO approaches. By partnering with seed companies worldwide, Cibus is transforming how crops are grown and helping to build a more productive and sustainable future for agriculture. For more information, please visit
www.cibus.com
.
About AgVayā
AgVayā was founded by industry leaders who recognized the critical need for practical, sustainable solutions in agriculture and food businesses – going beyond conventional advice to driving real transformation. With decades of experience in leading the companies and their global expansions, shaping board-level strategy, and driving growth across the agri-food value chain, our team specializes in business growth & strategy, organizational transformation, and talent & leadership development. For more information, please visit www.AgVayā.com.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of applicable securities laws, including The Private Securities Litigation Reform Act of 1995. All statements, other than statements of present or historical fact included herein, including statements regarding Cibus' operational and financial performance, Cibus' liquidity and capital resources, the implementation and execution of cost savings initiatives, Cibus' strategy, future operations, prospects, and plans, including the anticipated receipt of commercial revenues and additional funding, are forward-looking statements. Cibus' assessment of the period of time through which its financial resources will be adequate to support its operations is a forward-looking statement. Because this involves such risks and uncertainties, the Company could use its available capital resources sooner than it currently expects. Forward-looking statements may be identified by words such as "anticipate," "believe," "intend," "expect," "plan," "scheduled," "could," "would" and "will," or the negative of these and similar expressions.
These forward-looking statements are based on the current expectations and assumptions of Cibus' management about future events, which are based on currently available information. These forward-looking statements are subject to numerous risks and uncertainties, many of which are difficult to predict and beyond the control of Cibus. Cibus' actual results, level of activity, performance, or achievements could be materially different than those expressed, implied, or anticipated by forward-looking statements due to a variety of factors, including, but not limited to: Cibus' need for additional near-term funding to finance its activities and challenges in obtaining additional capital on acceptable terms, or at all; changes in expected or existing competition; challenges to Cibus' intellectual property protection and unexpected costs associated with defending intellectual property rights; increased or unanticipated time and resources required for Cibus' platform or trait product development efforts; Cibus' reliance on third parties in connection with its development activities; challenges associated with Cibus' ability to effectively license its productivity traits and sustainable ingredient products; the risk that farmers do not recognize the value in germplasm containing Cibus' traits or that farmers and processors fail to work effectively with crops containing Cibus' traits; delays or disruptions in the Company's platform or trait product development efforts, particularly with respect to its non-Rice and non-disease projects in light of the Company's realigned strategic priorities; challenges that arise in respect of Cibus' production of high-quality plants and seeds cost effectively on a large scale; Cibus' dependence on distributions from Cibus Global, LLC to pay taxes and cover its corporate and overhead expenses; regulatory developments that disfavor or impose significant burdens on gene-editing processes or products; delays and uncertainties regarding regulatory developments in the European Union; Cibus' ability to achieve commercial success; commodity prices and other market risks facing the agricultural sector; technological developments that could render Cibus' technologies obsolete; changes in macroeconomic and market conditions, including inflation, supply chain constraints, and rising interest rates; dislocations in the capital markets and challenges in accessing liquidity and the impact of such liquidity challenges on Cibus' ability to execute on its business plan; the Company's assessment of the period of time through which its financial resources will be adequate to support operations; and other important factors discussed in the "Risk Factors" section of Cibus' Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on March 20, 2025. Should one or more of these risks or uncertainties occur, or should underlying assumptions prove incorrect, actual results and plans could differ materially from those expressed in any forward-looking statements.
In addition, the forward-looking statements included in this press release represent Cibus' views as of the date hereof. Cibus specifically disclaims any obligation to update such forward-looking statements in the future, except as required under applicable law. These forward-looking statements should not be relied upon as representing Cibus' views as of any date subsequent to the date hereof.
CIBUS CONTACTS:
INVESTOR RELATIONS
Jeff Sonnek
[email protected]
MEDIA RELATIONS
Colin Sanford
[email protected]